Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Vitamin K for the Treatment of Cardiovascular Disease in End-Stage Renal Disease Patients: Is there Hope?

Author(s): Stefanos Roumeliotis, Athanasios Roumeliotis, Evangelia Dounousi, Theodoros Eleftheriadis and Vassilios Liakopoulos*

Volume 19, Issue 1, 2021

Published on: 20 March, 2020

Page: [77 - 90] Pages: 14

DOI: 10.2174/1570161118666200320111745

Price: $65

Abstract

In Chronic Kidney Disease, vascular calcification (VC) is highly prevalent even at early stages and is gradually enhanced, along with disease progression to End-Stage Renal Disease (ESRD). The calcification pattern in uremia includes all types of mineralization and contributes to the heavy cardiovascular (CV) burden that is common in these patients. Ectopic mineralization is the result of the imbalance between inhibitors and promoters of vascular calcification, with the latter overwhelming the former. The most powerful, natural inhibitor of calcification is Matrix Gla Protein (MGP), a small vitamin K dependent protein, secreted by chondrocytes and vascular smooth muscle cells. In uremia, MGP was reported as the only molecule able to reverse VC by “sweeping” calcium and hydroxyapatite crystals away from the arterial wall. To become biologically active, this protein needs to undergo carboxylation and phosphorylation, reactions highly dependent on vitamin K status. The inactive form of MGP reflects the deficiency of vitamin K and has been associated with CV events and mortality in ESRD patients. During the past decade, vitamin K status has emerged as a novel risk factor for vascular calcification and CV disease in various populations, including dialysis patients. This review presents evidence regarding the association between vitamin K and CV disease in ESRD patients, which are prone to atherosclerosis and atheromatosis.

Keywords: Cardiovascular disease, chronic kidney disease, end-stage renal disease, hemodialysis, matrix gla protein, vascular calcification, vitamin K.

« Previous
Graphical Abstract

[1]
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382(9888): 260-72.
[http://dx.doi.org/10.1016/S0140-6736(13)60687-X] [PMID: 23727169]
[2]
Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63(3): 1121-9.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00838.x] [PMID: 12631096]
[3]
Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16(2): 489-95.
[http://dx.doi.org/10.1681/ASN.2004030203] [PMID: 15590763]
[4]
Rahman M, Xie D, Feldman HI, et al. Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study. Am J Nephrol 2014; 40(5): 399-407.
[http://dx.doi.org/10.1159/000368915] [PMID: 25401485]
[5]
Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167(11): 1130-6.
[http://dx.doi.org/10.1001/archinte.167.11.1130] [PMID: 17563020]
[6]
Sedaghat S, Mattace-Raso FU, Hoorn EJ, et al. Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol 2015; 10(12): 2190-7.
[http://dx.doi.org/10.2215/CJN.03000315] [PMID: 26563380]
[7]
Renal U. .USRDS 2007 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2008; 51(1): Supp 1.Available at. https://www.usrds.org/
[8]
Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National kidney foundation task force on cardiovascular disease. Am J Kidney Dis 1998; 32(5): 853-906.
[http://dx.doi.org/10.1016/S0272-6386(98)70145-3] [PMID: 9820460]
[9]
Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380(9854): 1649-61.
[http://dx.doi.org/10.1016/S0140-6736(12)61272-0] [PMID: 23013600]
[10]
Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017; 20173081856
[http://dx.doi.org/10.1155/2017/3081856] [PMID: 29138677]
[11]
Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5(1): 185-97.
[http://dx.doi.org/10.2147/VHRM.S4822] [PMID: 19436645]
[12]
Doherty TM, Detrano RC. Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int 1994; 54(3): 224-30.
[http://dx.doi.org/10.1007/BF00301683] [PMID: 8055371]
[13]
Temmar M, Liabeuf S, Renard C, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010; 28(1): 163-9.
[http://dx.doi.org/10.1097/HJH.0b013e328331b81e] [PMID: 19927012]
[14]
Roumeliotis A, Roumeliotis S, Panagoutsos S, et al. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease. Ren Fail 2019; 41(1): 131-8.
[http://dx.doi.org/10.1080/0886022X.2019.1585372] [PMID: 30909780]
[15]
Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21(12): 1998-2003.
[http://dx.doi.org/10.1161/hq1201.100229] [PMID: 11742876]
[16]
Schlieper G, Westenfeld R, Brandenburg V, Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial 2007; 20(2): 113-21.
[http://dx.doi.org/10.1111/j.1525-139X.2007.00257.x] [PMID: 17374084]
[17]
Shearer MJ, Vitamin K, Vitamin K. Lancet 1995; 345(8944): 229-34.
[http://dx.doi.org/10.1016/S0140-6736(95)90227-9] [PMID: 7823718]
[18]
Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr 2012; 3(2): 182-95.
[http://dx.doi.org/10.3945/an.111.001800] [PMID: 22516726]
[19]
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis 2000; 30(6): 298-307.
[PMID: 11356998]
[20]
Vermeer C, Shearer MJ, Zittermann A, et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr 2004; 43(6): 325-35.
[http://dx.doi.org/10.1007/s00394-004-0480-4] [PMID: 15309455]
[21]
Stafford DW. The vitamin K cycle. J Thromb Haemost 2005; 3(8): 1873-8.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01419.x] [PMID: 16102054]
[22]
Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117(3): 765-71.
[http://dx.doi.org/10.1016/0006-291X(83)91663-7] [PMID: 6607731]
[23]
Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.
[http://dx.doi.org/10.1038/386078a0] [PMID: 9052783]
[24]
Roumeliotis S, Roumeliotis A, Panagoutsos S, et al. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J Diabetes Complications 2017; 31(10): 1527-32.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.06.012] [PMID: 28734846]
[25]
Shanahan CM. Mechanisms of vascular calcification in renal disease. Clin Nephrol 2005; 63(2): 146-57.
[http://dx.doi.org/10.5414/CNP63146] [PMID: 15730057]
[26]
Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91(4): 1800-9.
[http://dx.doi.org/10.1172/JCI116391] [PMID: 8473518]
[27]
Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002; 277(6): 4388-94.
[http://dx.doi.org/10.1074/jbc.M109683200] [PMID: 11741887]
[28]
Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003; 1(1): 178-85.
[http://dx.doi.org/10.1046/j.1538-7836.2003.00023.x] [PMID: 12871556]
[29]
Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost 2000; 84(6): 1039-44.
[PMID: 11154111]
[30]
Chatrou ML, Cleutjens JP, van der Vusse GJ, Roijers RB, Mutsaers PH, Schurgers LJ. Intra-section analysis of human coronary arteries reveals a potential role for micro-calcifications in macrophage recruitment in the early stage of atherosclerosis. PLoS One 2015; 10(11)e0142335
[http://dx.doi.org/10.1371/journal.pone.0142335] [PMID: 26555788]
[31]
Roijers RB, Debernardi N, Cleutjens JPS, Schurgers LJ, Mutsaers PH, van der Vusse GJ. Microcalcifications in early intimal lesions of atherosclerotic human coronary arteries. Am J Pathol 2011; 178(6): 2879-87.
[http://dx.doi.org/10.1016/j.ajpath.2011.02.004] [PMID: 21531376]
[32]
Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, et al. Circulating species of matrix Gla protein and the risk of vascular calcification in healthy women. Int J Cardiol 2013; 168(6): e168-70.
[http://dx.doi.org/10.1016/j.ijcard.2013.08.062] [PMID: 24029658]
[33]
Rennenberg RJ, de Leeuw PW, Kessels AG, et al. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest 2010; 40(4): 344-9.
[http://dx.doi.org/10.1111/j.1365-2362.2010.02275.x] [PMID: 20486996]
[34]
Cranenburg EC, Brandenburg VM, Vermeer C, et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009; 101(2): 359-66.
[http://dx.doi.org/10.1160/TH08-04-0241] [PMID: 19190822]
[35]
Cranenburg EC, Vermeer C, Koos R, et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008; 45(5): 427-36.
[http://dx.doi.org/10.1159/000124863] [PMID: 18401181]
[36]
Schurgers LJ, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25(8): 1629-33.
[http://dx.doi.org/10.1161/01.ATV.0000173313.46222.43] [PMID: 15961706]
[37]
Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant 2014; 29(7): 1385-90.
[http://dx.doi.org/10.1093/ndt/gft464] [PMID: 24285428]
[38]
Sardana M, Vasim I, Varakantam S, et al. Inactive matrix gla-protein and arterial stiffness in type 2 diabetes mellitus. Am J Hypertens 2017; 30(2): 196-201.
[http://dx.doi.org/10.1093/ajh/hpw146] [PMID: 27927630]
[39]
Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152(10): 640-8.
[http://dx.doi.org/10.7326/0003-4819-152-10-201005180-00004] [PMID: 20479029]
[40]
Mayer O Jr, Seidlerová J, Vaněk J, et al. The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. Int J Cardiol 2016; 203: 916-22.
[http://dx.doi.org/10.1016/j.ijcard.2015.10.226] [PMID: 26618253]
[41]
Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010; 5(4): 568-75.
[http://dx.doi.org/10.2215/CJN.07081009] [PMID: 20133489]
[42]
Barrett H, O’Keeffe M, Kavanagh E, Walsh M, O’Connor EM. Is matrix gla protein associated with vascular calcification? A systematic review. Nutrients 2018; 10(4): 415.
[http://dx.doi.org/10.3390/nu10040415] [PMID: 29584693]
[43]
Zwakenberg SR, van der Schouw YT, Vermeer C, Pasterkamp G, den Ruijter HM, Beulens JWJ. Matrix gla protein, plaque stability, and cardiovascular events in patients with severe atherosclerotic disease. Cardiology 2018; 141(1): 32-6.
[http://dx.doi.org/10.1159/000493006] [PMID: 30304721]
[44]
Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the inactive circulating matrix gla protein with vitamin k intake, calcification, mortality, and cardiovascular disease: A review. Int J Mol Sci 2019; 20(3): 628.
[http://dx.doi.org/10.3390/ijms20030628] [PMID: 30717170]
[45]
Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost 2015; 113(5): 1135-44.
[http://dx.doi.org/10.1160/TH14-08-0675] [PMID: 25694037]
[46]
Pivin E, Ponte B, Pruijm M, et al. Inactive Matrix gla-protein is associated with arterial stiffness in an adult population-based study. Hypertension 2015; 66(1): 85-92.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05177] [PMID: 25987667]
[47]
Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115(24): 5121-3.
[http://dx.doi.org/10.1182/blood-2010-01-264598] [PMID: 20354170]
[48]
Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, et al. Circulating desphospho-uncarboxylated matrix γ-carboxyglutamate protein and the risk of coronary heart disease and stroke. J Thromb Haemost 2014; 12(7): 1028-34.
[http://dx.doi.org/10.1111/jth.12609] [PMID: 24826813]
[49]
van den Heuvel EG, van Schoor NM, Lips P, et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas 2014; 77(2): 137-41.
[http://dx.doi.org/10.1016/j.maturitas.2013.10.008] [PMID: 24210635]
[50]
Liu YP, Gu YM, Thijs L, et al. Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population. Hypertension 2015; 65(2): 463-70.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04494] [PMID: 25421980]
[51]
Thamratnopkoon S, Susantitaphong P, Tumkosit M, et al. Correlations of plasma desphosphorylated uncarboxylated matrix gla protein with vascular calcification and vascular stiffness in chronic kidney disease. Nephron 2017; 135(3): 167-72.
[http://dx.doi.org/10.1159/000453368] [PMID: 27951533]
[52]
Puzantian H, Akers SR, Oldland G, et al. Circulating dephospho-uncarboxylated matrix gla-protein is associated with kidney dysfunction and arterial stiffness. Am J Hypertens 2018; 31(9): 988-94.
[http://dx.doi.org/10.1093/ajh/hpy079] [PMID: 29788226]
[53]
Brancaccio D, Biondi ML, Gallieni M, et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25(6): 548-52.
[http://dx.doi.org/10.1159/000088809] [PMID: 16210837]
[54]
Sheng K, Zhang P, Lin W, Cheng J, Li J, Chen J. Association of Matrix Gla protein gene (rs1800801, rs1800802, rs4236) polymorphism with vascular calcification and atherosclerotic disease: a meta-analysis. Sci Rep 2017; 7(1): 8713.
[http://dx.doi.org/10.1038/s41598-017-09328-5] [PMID: 28821877]
[55]
Osman NA, El-Abd N, Nasrallah M. VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis. Saudi J Kidney Dis Transpl 2016; 27(5): 908-15.
[http://dx.doi.org/10.4103/1319-2442.190782] [PMID: 27751997]
[56]
Fain ME, Kapuku GK, Paulson WD, et al. Inactive matrix gla protein, arterial stiffness, and endothelial function in African American hemodialysis patients. Am J Hypertens 2018; 31(6): 735-41.
[http://dx.doi.org/10.1093/ajh/hpy049] [PMID: 29635270]
[57]
Shea MK, O’Donnell CJ, Vermeer C, et al. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr 2011; 141(8): 1529-34.
[http://dx.doi.org/10.3945/jn.111.139634] [PMID: 21628633]
[58]
Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 2014; 15: 145.
[http://dx.doi.org/10.1186/1471-2369-15-145] [PMID: 25190488]
[59]
Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22(2): 387-95.
[http://dx.doi.org/10.1681/ASN.2010040339] [PMID: 21289218]
[60]
Cranenburg EC, Koos R, Schurgers LJ, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010; 104(4): 811-22.
[http://dx.doi.org/10.1160/TH09-11-0786] [PMID: 20694284]
[61]
Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18(9): 1400-7.
[http://dx.doi.org/10.1161/01.ATV.18.9.1400] [PMID: 9743228]
[62]
McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int 2013; 83(5): 835-44.
[http://dx.doi.org/10.1038/ki.2012.477] [PMID: 23344475]
[63]
Kaesler N, Magdeleyns E, Herfs M, et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 2014; 86(2): 286-93.
[http://dx.doi.org/10.1038/ki.2013.530] [PMID: 24429407]
[64]
Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109(7): 2823-31.
[http://dx.doi.org/10.1182/blood-2006-07-035345] [PMID: 17138823]
[65]
Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40(6): 531-7.
[http://dx.doi.org/10.1159/000075344] [PMID: 14654717]
[66]
Scheiber D, Veulemans V, Horn P, et al. High-dose menaquinone-7 supplementation reduces cardiovascular calcification in a murine model of extraosseous calcification. Nutrients 2015; 7(8): 6991-7011.
[http://dx.doi.org/10.3390/nu7085318] [PMID: 26295257]
[67]
Zaragatski E, Grommes J, Schurgers LJ, et al. Vitamin K antagonism aggravates chronic kidney disease-induced neointimal hyperplasia and calcification in arterialized veins: role of vitamin K treatment? Kidney Int 2016; 89(3): 601-11.
[http://dx.doi.org/10.1038/ki.2015.298] [PMID: 26466318]
[68]
Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the rotterdam study. J Nutr 2004; 134(11): 3100-5.
[http://dx.doi.org/10.1093/jn/134.11.3100] [PMID: 15514282]
[69]
Cheung CL, Sahni S, Cheung BM, Sing CW, Wong IC. Vitamin K intake and mortality in people with chronic kidney disease from NHANES III. Clin Nutr 2015; 34(2): 235-40.
[http://dx.doi.org/10.1016/j.clnu.2014.03.011] [PMID: 24745600]
[70]
Riphagen IJ, Keyzer CA, Drummen NEA, et al. Prevalence and effects of functional vitamin K insufficiency: the prevend study. Nutrients 2017; 9(12): 1334.
[http://dx.doi.org/10.3390/nu9121334] [PMID: 29292751]
[71]
Juanola-Falgarona M, Salas-Salvadó J, Martínez-González MA, et al. Dietary intake of vitamin K is inversely associated with mortality risk. J Nutr 2014; 144(5): 743-50.
[http://dx.doi.org/10.3945/jn.113.187740] [PMID: 24647393]
[72]
Zwakenberg SR, den Braver NR, Engelen AIP, et al. Vitamin K intake and all-cause and cause specific mortality. Clin Nutr 2017; 36(5): 1294-300.
[http://dx.doi.org/10.1016/j.clnu.2016.08.017] [PMID: 27640076]
[73]
Chen HG, Sheng LT, Zhang YB, et al. Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis. Eur J Nutr 2019; 58(6): 2191-205.
[http://dx.doi.org/10.1007/s00394-019-01998-3] [PMID: 31119401]
[74]
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 2010; 5(4): 590-7.
[http://dx.doi.org/10.2215/CJN.06420909] [PMID: 20167683]
[75]
Voong K, Harrington D, Goldsmith D. Vitamin K status in chronic kidney disease: a report of a study and a mini-review. Int Urol Nephrol 2013; 45(5): 1339-44.
[http://dx.doi.org/10.1007/s11255-012-0367-x] [PMID: 23296791]
[76]
Cranenburg EC, Schurgers LJ, Uiterwijk HH, et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int 2012; 82(5): 605-10.
[http://dx.doi.org/10.1038/ki.2012.191] [PMID: 22648294]
[77]
Elliott MJ, Booth SL, Hopman WM, Holden RM. Assessment of potential biomarkers of subclinical vitamin K deficiency in patients with end-stage kidney disease. Can J Kidney Health Dis 2014; 1(1): 13.
[http://dx.doi.org/10.1186/2054-3581-1-13] [PMID: 25780608]
[78]
Wyskida K, Żak-Gołąb A, Wajda J, et al. Functional deficiency of vitamin K in hemodialysis patients in Upper Silesia in Poland. Int Urol Nephrol 2016; 48(5): 765-71.
[http://dx.doi.org/10.1007/s11255-016-1255-6] [PMID: 27000106]
[79]
Fusaro M, D’Alessandro C, Noale M, et al. Low vitamin K1 intake in haemodialysis patients. Clin Nutr 2017; 36(2): 601-7.
[http://dx.doi.org/10.1016/j.clnu.2016.04.024] [PMID: 27234935]
[80]
Fusaro M, Noale M, Viola V, et al. Vitamin K, vertebral fractures, vascular calcifications, and mortality: vitamin K Italian (VIKI) dialysis study. J Bone Miner Res 2012; 27(11): 2271-8.
[http://dx.doi.org/10.1002/jbmr.1677] [PMID: 22692665]
[81]
Pilkey RM, Morton AR, Boffa MB, et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49(3): 432-9.
[http://dx.doi.org/10.1053/j.ajkd.2006.11.041] [PMID: 17336705]
[82]
Wyskida K, Żak-Gołąb A, Łabuzek K, et al. Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. Clin Biochem 2015; 48(18): 1246-51.
[http://dx.doi.org/10.1016/j.clinbiochem.2015.08.011] [PMID: 26282719]
[83]
Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59(2): 186-95.
[http://dx.doi.org/10.1053/j.ajkd.2011.10.041] [PMID: 22169620]
[84]
Feng Y, Ruan Y, He Q, Zhang W, Wang L. Suboptimal vitamin K status and its risk factors in a population of Chinese chronic hae-modialysis patients. Nephrology (Carlton) 2015; 20(9): 625-31.
[http://dx.doi.org/10.1111/nep.12494] [PMID: 25917879]
[85]
Xu Q, Guo H, Cao S, et al. Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients. Int Urol Nephrol 2019; 51(3): 527-34.
[http://dx.doi.org/10.1007/s11255-019-02080-x] [PMID: 30689181]
[86]
Stankowiak-Kulpa H, Krzyżanowska P, Kozioł L, et al. Vitamin K status in peritoneally dialyzed patients with chronic kidney disease. Acta Biochim Pol 2011; 58(4): 617-20.
[http://dx.doi.org/10.18388/abp.2011_2232] [PMID: 22187681]
[87]
Holden RM, Iliescu E, Morton AR, Booth SL. Vitamin K status of Canadian peritoneal dialysis patients. Perit Dial Int 2008; 28(4): 415-8.
[http://dx.doi.org/10.1177/089686080802800419] [PMID: 18556387]
[88]
Vychytil A, Druml W. Vitamin K supplementation in patients on continuous ambulatory peritoneal dialysis. Lancet 1998; 351(9117): 1734-5.
[http://dx.doi.org/10.1016/S0140-6736(05)77772-2] [PMID: 9734914]
[89]
van Ballegooijen AJ, Beulens JWJ, Keyzer CA, et al. Joint association of vitamins D and K status with long-term outcomes in stable kidney transplant recipients. Nephrol Dial Transplant 2019.Available at; https://www.mdlinx.com/journal-summary/joint-association-of-vitamins-d-and-k-status-with-long-term-outcomes-in-stable-kidney transplant/7J7VMaQw37dV svnRe5Ptsr?print preview=1&spec=nephrology .
[http://dx.doi.org/10.1093/ndt/gfy399] [PMID: 30753729]
[90]
Keyzer CA, Vermeer C, Joosten MM, et al. Vitamin K status and mortality after kidney transplantation: a cohort study. Am J Kidney Dis 2015; 65(3): 474-83.
[http://dx.doi.org/10.1053/j.ajkd.2014.09.014] [PMID: 25453995]
[91]
Boxma PY, van den Berg E, Geleijnse JM, et al. Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS One 2012; 7(10)e47991
[http://dx.doi.org/10.1371/journal.pone.0047991] [PMID: 23118917]
[92]
Jansz TT, Neradova A, van Ballegooijen AJ, et al. The role of kidney transplantation and phosphate binder use in vitamin K status. PLoS One 2018; 13(8)e0203157
[http://dx.doi.org/10.1371/journal.pone.0203157] [PMID: 30161193]
[93]
Lees JS, Chapman FA, Witham MD, Jardine AG, Mark PB. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis. Heart 2019; 105(12): 938-45.
[PMID: 30514729]
[94]
Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89(6): 1799-807.
[http://dx.doi.org/10.3945/ajcn.2008.27338] [PMID: 19386744]
[95]
Brandenburg VM, Reinartz S, Kaesler N, et al. Slower progress of aortic valve calcification with vitamin k supplementation: results from a prospective interventional proof-of-concept study. Circulation 2017; 135(21): 2081-3.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.027011] [PMID: 28533322]
[96]
Dalmeijer GW, van der Schouw YT, Magdeleyns E, Ahmed N, Vermeer C, Beulens JW. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 2012; 225(2): 397-402.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.09.019] [PMID: 23062766]
[97]
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Plasma desphospho-uncarboxylated matrix gla protein as a marker of kidney damage and cardiovascular risk in advanced stage of chronic kidney disease. Kidney Blood Press Res 2016; 41(3): 231-9.
[http://dx.doi.org/10.1159/000443426] [PMID: 27100101]
[98]
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5. Pol Arch Med Wewn 2015; 125(9): 631-40.
[http://dx.doi.org/10.20452/pamw.3041] [PMID: 26176325]
[99]
Mansour AG, Hariri E, Daaboul Y, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J Am Soc Hypertens 2017; 11(9): 589-97.
[http://dx.doi.org/10.1016/j.jash.2017.07.001] [PMID: 28756183]
[100]
Nagasawa Y, Fujii M, Kajimoto Y, Imai E, Hori M. Vitamin K2 and serum cholesterol in patients on continuous ambulatory peritoneal dialysis. Lancet 1998; 351(9104): 724.
[http://dx.doi.org/10.1016/S0140-6736(05)78492-0] [PMID: 9504520]
[101]
Aoun M, Makki M, Azar H, Matta H, Chelala DN. High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial. BMC Nephrol 2017; 18(1): 191.
[http://dx.doi.org/10.1186/s12882-017-0609-3] [PMID: 28592319]
[102]
Oikonomaki T, Papasotiriou M, Ntrinias T, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. Int Urol Nephrol 2019; 51(11): 2037-44.
[http://dx.doi.org/10.1007/s11255-019-02275-2] [PMID: 31529295]
[103]
Eleftheriadis T, Leivaditis K, Antoniadi G, Liakopoulos V. Calciphylaxis: current management and emerging therapies. J Nephrol Ther 2012; S1: 1-5.
[104]
Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32(1): 126-32.
[PMID: 26908770]
[105]
Nigwekar SU, Bloch DB, Nazarian RM, et al. Vitamin K-dependent carboxylation of matrix gla protein influences the risk of calciphylaxis. J Am Soc Nephrol 2017; 28(6): 1717-22.
[http://dx.doi.org/10.1681/ASN.2016060651] [PMID: 28049648]
[106]
Delanaye P, Dubois BE, Lukas P, et al. Impact of stopping vitamin K antagonist therapy on concentrations of dephospho-uncarboxylated Matrix Gla protein. Clin Chem Lab Med 2015; 53(8): e191-3.
[http://dx.doi.org/10.1515/cclm-2015-0073] [PMID: 25781548]
[107]
Christiadi D, Singer RF. Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation. Clin Kidney J 2018; 11(4): 528-9.
[http://dx.doi.org/10.1093/ckj/sfx126] [PMID: 30094016]
[108]
Holden RM, Booth SL, Day AG, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis 2015; 2(1): 17.
[http://dx.doi.org/10.1186/s40697-015-0053-x] [PMID: 26075081]
[109]
Krueger T, Schlieper G, Schurgers L, et al. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant 2014; 29(9): 1633-8.
[http://dx.doi.org/10.1093/ndt/gft459] [PMID: 24285427]
[110]
Pucaj K, Rasmussen H, Møller M, Preston T. Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7. Toxicol Mech Methods 2011; 21(7): 520-32.
[http://dx.doi.org/10.3109/15376516.2011.568983] [PMID: 21781006]
[111]
Theuwissen E, Cranenburg EC, Knapen MH, et al. Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects. Br J Nutr 2012; 108(9): 1652-7.
[http://dx.doi.org/10.1017/S0007114511007185] [PMID: 22289649]
[112]
Vissers LE, Dalmeijer GW, Boer JM, Monique Verschuren WM, van der Schouw YT, Beulens JW. Intake of dietary phylloquinone and menaquinones and risk of stroke. J Am Heart Assoc 2013; 2(6)e000455
[http://dx.doi.org/10.1161/JAHA.113.000455] [PMID: 24326161]
[113]
Gundberg CM, Lian JB, Booth SL. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 2012; 3(2): 149-57.
[http://dx.doi.org/10.3945/an.112.001834] [PMID: 22516722]
[114]
Takagi K, Masuda K, Yamazaki M, et al. Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 2010; 73(1): 30-5.
[http://dx.doi.org/10.5414/CNP73030] [PMID: 20040349]
[115]
Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol 2017; 18(1): 149.
[http://dx.doi.org/10.1186/s12882-017-0560-3] [PMID: 28464802]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy